Interindividual variability in genes encoding drug-metabolizing enzymes, transporters,
receptors, and human leukocyte antigens has a major impact on a patient's response to …

Psychotropic medication efficacy and tolerability are critical treatment issues faced by
individuals with psychiatric disorders and their healthcare providers. For some people, it can …

Background: Atrial fibrillation (AF) is the leading cause of ischemic stroke and treatment has
focused on reducing this risk through anticoagulation. Direct Oral Anticoagulants (DOACs) …

Pharmacogenomics (PGx) aims at tailoring drug therapy by considering patient genetic
makeup. While drug dosage guidelines have been extensively based on single gene …

The inadequate efficacy and adverse effects of antipsychotics severely affect the recovery of
patients with schizophrenia spectrum disorders (SSD). We report the evidence for …

Cardiovascular disease remains a leading cause of both morbidity and mortality worldwide.
It is widely accepted that both concomitant medications (drug–drug interactions, DDIs) and …

The origins of pharmacogenetics date back to the 1950s, when it was established that inter-
individual differences in drug response are partially determined by genetic factors. Since …

Polygenic models have emerged as promising prediction tools for the prediction of complex
traits. Currently, the majority of polygenic models are developed in the context of predicting …

Antipsychotic-induced weight gain (AIWG) is a common side effect of antipsychotic
medication and may contribute to diabetes and coronary heart disease. To expand the …

Using Swedish registers, we examine whether the prescription of and the response to
antidepressants (AD), mood stabilizers (MS), and antipsychotics (AP) in the treatment of …